Massachusetts Financial Services Co. MA Takes Position in GRAIL, Inc. $GRAL

Massachusetts Financial Services Co. MA bought a new position in shares of GRAIL, Inc. (NASDAQ:GRAL) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 13,943 shares of the company’s stock, valued at approximately $952,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Handelsbanken Fonder AB boosted its stake in GRAIL by 74.5% during the 2nd quarter. Handelsbanken Fonder AB now owns 16,400 shares of the company’s stock valued at $1,120,000 after purchasing an additional 7,000 shares during the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in shares of GRAIL in the second quarter worth approximately $207,000. 180 Wealth Advisors LLC raised its stake in shares of GRAIL by 0.3% in the second quarter. 180 Wealth Advisors LLC now owns 127,774 shares of the company’s stock worth $8,723,000 after purchasing an additional 427 shares during the last quarter. Moody National Bank Trust Division bought a new position in shares of GRAIL in the second quarter valued at approximately $908,000. Finally, PVG Asset Management Corp boosted its position in shares of GRAIL by 167.8% during the first quarter. PVG Asset Management Corp now owns 25,907 shares of the company’s stock valued at $1,339,000 after buying an additional 16,234 shares during the last quarter.

Insider Activity

In other news, insider Andrew John Partridge sold 1,491 shares of GRAIL stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $61.08, for a total transaction of $91,070.28. Following the sale, the insider directly owned 163,738 shares in the company, valued at $10,001,117.04. The trade was a 0.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.83% of the stock is currently owned by corporate insiders.

GRAIL Stock Down 0.5%

GRAL stock opened at $67.87 on Friday. The firm has a market cap of $3.03 billion, a PE ratio of -6.96 and a beta of 3.24. The business has a 50 day moving average of $67.58 and a 200-day moving average of $65.35. GRAIL, Inc. has a 12-month low of $29.95 and a 12-month high of $118.84.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.10. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%.The business had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. On average, research analysts expect that GRAIL, Inc. will post -10.41 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on GRAL. Piper Sandler upped their price target on GRAIL from $54.00 to $56.00 and gave the stock a “neutral” rating in a report on Wednesday, May 6th. The Goldman Sachs Group initiated coverage on GRAIL in a research note on Friday, June 5th. They set a “neutral” rating and a $60.00 price objective on the stock. Wolfe Research initiated coverage on shares of GRAIL in a research note on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Robert W. Baird set a $70.00 target price on shares of GRAIL in a report on Wednesday, May 6th. Finally, TD Cowen reiterated a “buy” rating on shares of GRAIL in a report on Wednesday, July 15th. Four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $67.78.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.